Cost Analyses of Adjunct Colony Stimulating Factors for Acute Leukemia: Can They Improve Clinical Decision Making

References

• Ohno R, Tomonago M, Kobayashi T, et al. Effect of granulocyte colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990; 323: 871
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Koenigsmann M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991; 78: 1190–97
   PubMed Web of Science ®Google Scholar
• Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995; 332: 1671–83
   PubMed Web of Science ®Google Scholar
• Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336: 1781–87
   PubMed Web of Science ®Google Scholar
• Heil G, Hoelzer D, Sanz MA, et al. A randomized double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997; 90: 4710–18
   PubMed Web of Science ®Google Scholar
• Godwin JE, Kopecky K, Head DR, et al. A double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia. A Southwest Oncology Group Study. Blood 1998; 91: 3607–15
   PubMed Web of Science ®Google Scholar
• Rowe JM, Anderson JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group. Blood 1995; 86: 457–62
   PubMed Web of Science ®Google Scholar
• Rowe JM, Rubin A, Mazza JJ, . Incidence of infections in adult patients with acute myeloid leukemia treated with yeast-derived GM-CSF: Results of a double blind prospective study by the Eastern Cooperative Oncology Group. Acute Leukemias V, Hiddemann, et al. Springer-Verlag, HeidelbergGermany 1996
   Google Scholar
• Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1996; 64: 328–40
   Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896–03
   PubMed Web of Science ®Google Scholar
• Desch CE, Ozer H. Neutropenia and neoplasia: An overview of the pharmacoeconomics of sargramostim in cancer therapy. Clin Ther 1997; 19: 847–65
   PubMed Web of Science ®Google Scholar
• Laver J, Amylon M, Desai S, et al. Effects of r-metHuG-CSF in an intensive treatment for T-cell leukemia and advanced stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. J Clin Oncol 1998; 16(2)522–526
   PubMed Web of Science ®Google Scholar
• Bennett CL, Stinson TJ, Lane D, et al. A cost-analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic leukemia: A case for prospective economic analysis in a cooperative trial. Med Ped Onc 1999, in press
   Google Scholar
• Lu ZJ, Luo R, Erder H, et al. Cost impact of filgrastim as an adjunct to chemotherapy for patients with acute myeloid leukemia. Proceedings of the American Society of Hematology. 1996, 826a
   Google Scholar
• Bennett CL, Hynes DM, Godwin JE, et al. Economic analysis of granulocyte colony-stimulating factor as adjunct therapy for older patients with AML: Estimates from a SWOG clinical trial. Proceedings of the American Society of Hematology. 1998, 2538a
   Google Scholar
• Bennett CL, Stinson TJ, Tallman MS, et al. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factro in adult patients with acute myelogenous leukemia. Ann Oncol 1999; 10: 177–82
   PubMed Web of Science ®Google Scholar
• The American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic growth factors: evidence based clinical practice guidelines. J Clin Oncol 1994; 12: 2471–2508
   PubMed Web of Science ®Google Scholar
• The American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 1996; 14: 1957–1960
   PubMed Web of Science ®Google Scholar
• Drummond MF, Menzin J, Oster G. Problems in undertaking pharmacoenomic assessments in phase III clinical trials: The case of colony stimulating factors. Quality of Life and Pharmacoenomics in Clinical Trials, B. Spilker. Lippincott-Raven Publishers, Phila, Pa 1996
   Google Scholar
• Hillner BE, Smith T.J. Does a clinical trial warrant an economic analysis. J Natl Cancer Inst 1998; 90: 724–5
   PubMed Web of Science ®Google Scholar